Amazing stuff!
Apparently, this is not a new development. See e.g. FORMULATION DEVELOPMENT – Deuterium Modification as a New Branch of Medicinal Chemistry to Develop Novel, Highly Differentiated Drugs (dated July/August 2012)
"Drugs made with deuterium take advantage of the fact that it’s harder to remove a deuterium from a carbon than it is to remove a hydrogen. Enzymes in the body’s metabolism often start degrading drugs by cleaving off their hydrogens. Because deuteriums are harder to pick off, the drugs could remain intact longer."
"The company generated pre-clinical validation of DO-2, a novel, highly selective, brain penetrant deuterated MET kinase and RAS pathway inhibitor. ... initial idea for the use of deuteration as a means to modulate metabolic properties of the parent drug ..."
"An investigational JAK 1/2 inhibitor for alopecia areata Concert Pharmaceuticals is developing deuruxolitinib , an oral inhibitor of Janus kinases JAK1 and JAK2, as a potential treatment for alopecia areata. ... Deuruxolitinib is a deuterium-modified JAK 1/2 inhibitor. ..."
No comments:
Post a Comment